Insulin glulisine

Insulin glulisine
	PDB: 6gv0
Clinical data
Trade names	Apidra, Apidra Solostar
AHFS/Drugs.com	Monograph
MedlinePlus	a607033
License data	US DailyMed: Insulin glulisine;
Pregnancy; category	AU: B3;
Routes of; administration	Subcutaneous, intravenous
ATC code	A10AB06 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); UK: POM (Prescription only); US: ℞-only; EU: Rx-only;
Identifiers
CAS Number	207748-29-6 ;
DrugBank	DB01309 ;
ChemSpider	none;
UNII	7XIY785AZD;
KEGG	D04540 ;
PDB ligand	6gv0 (PDBe, RCSB PDB);
Chemical and physical data
Formula	C258H384N64O78S6
Molar mass	5822.64 g·mol−1
	(what is this?) (verify)

Insulin glulisine, sold under the brand name Apidra among others, is a rapid-acting modified form of medical insulin used for the treatment of diabetes. It differs from human insulin in that the amino acid asparagine at position B3 is replaced by lysine and the lysine in position B29 is replaced by glutamic acid. When injected subcutaneously, it appears in the blood earlier than regular human insulin (RHI). Intravenous injections may be used for extreme hyperglycemia. It was developed by Sanofi-Aventis.

The most common side effects include hypoglycaemia (low blood glucose levels).

Insulin glulisine was approved for medical use in the United States and in the European Union in 2004.